LEVOTHYROXINE SODIUM

Drug Alvogen Inc
Total Payments
$375,554
Transactions
6
Doctors
1
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2022 $1,000 1 1
2021 $374,554 5 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $374,554 5 99.7%
Consulting Fee $1,000 1 0.3%

Payments by Type

Research
$374,554
5 transactions
General
$1,000
1 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A RANDOMIZED, OPEN-LABEL, PARALLEL-DESIGN, ONE-PERIOD, TWO TREATMENT, PILOT RELATIVE BIOAVAILABILITY STUDY OF BALOXAVIR MARBOXIL TABLETS, 40 MG MANUFACTURED BY NORWICH PHARMACEUTICALS INC, NY 13815 AND XOFLUZA (BALOXAVIR MARBOXIL) TABLETS, 40 MG MANUFACTURED BY SHIONOGI PHARMA CO., LTD., JAPAN IN HEALTHY ADULT SUBJECTS UNDER FASTING CONDITIONS Alvogen Inc $374,554 0

Top Doctors Receiving Payments for LEVOTHYROXINE SODIUM

Doctor Specialty Location Total Records
Unknown Las Vegas, NV $374,554 5
Irwin Klein New Hyde Park, NY $1,000 1

About LEVOTHYROXINE SODIUM

LEVOTHYROXINE SODIUM is a drug associated with $375,554 in payments to 1 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Alvogen Inc.

Payment data is available from 2021 to 2022. In 2022, $1,000 was paid across 1 transactions to 1 doctors.

The most common payment nature for LEVOTHYROXINE SODIUM is "Unspecified" ($374,554, 99.7% of total).

LEVOTHYROXINE SODIUM is associated with 1 research study, including "A RANDOMIZED, OPEN-LABEL, PARALLEL-DESIGN, ONE-PERIOD, TWO TREATMENT, PILOT RELATIVE BIOAVAILABILITY STUDY OF BALOXAVIR MARBOXIL TABLETS, 40 MG MANUFACTURED BY NORWICH PHARMACEUTICALS INC, NY 13815 AND XOFLUZA (BALOXAVIR MARBOXIL) TABLETS, 40 MG MANUFACTURED BY SHIONOGI PHARMA CO., LTD., JAPAN IN HEALTHY ADULT SUBJECTS UNDER FASTING CONDITIONS" ($374,554).